iRadimed (NASDAQ:IRMD) CEO Sells $388,450.00 in Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the company’s stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $77.69, for a total value of $388,450.00. Following the completion of the sale, the chief executive officer owned 2,327,500 shares in the company, valued at $180,823,475. The trade was a 0.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

iRadimed Trading Up 0.5%

iRadimed stock opened at $76.81 on Friday. iRadimed Corporation has a 12 month low of $46.86 and a 12 month high of $80.64. The stock’s 50 day simple moving average is $73.14 and its two-hundred day simple moving average is $63.67. The firm has a market cap of $976.64 million, a PE ratio of 47.41 and a beta of 1.02.

Hedge Funds Weigh In On iRadimed

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in iRadimed by 3.3% during the first quarter. Vanguard Group Inc. now owns 554,451 shares of the medical equipment provider’s stock valued at $29,098,000 after purchasing an additional 17,640 shares in the last quarter. Geode Capital Management LLC boosted its holdings in iRadimed by 6.5% in the 2nd quarter. Geode Capital Management LLC now owns 261,386 shares of the medical equipment provider’s stock worth $15,630,000 after buying an additional 15,996 shares during the last quarter. Ranger Investment Management L.P. boosted its holdings in iRadimed by 7.4% in the 2nd quarter. Ranger Investment Management L.P. now owns 214,840 shares of the medical equipment provider’s stock worth $12,845,000 after buying an additional 14,730 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in iRadimed by 1.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider’s stock worth $8,889,000 after buying an additional 1,821 shares in the last quarter. Finally, Acadian Asset Management LLC raised its holdings in shares of iRadimed by 10.9% during the first quarter. Acadian Asset Management LLC now owns 156,319 shares of the medical equipment provider’s stock valued at $8,197,000 after acquiring an additional 15,329 shares during the last quarter. 92.34% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on IRMD. Wall Street Zen downgraded shares of iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Weiss Ratings reissued a “buy (b)” rating on shares of iRadimed in a research note on Friday. Finally, Roth Capital set a $90.00 target price on shares of iRadimed in a research note on Friday. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $81.00.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.